The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
American Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
AJCC Cancer Staging Manual, 6th edition
Schmoll, H.-J. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg077 · Cited by 729
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Research works printed but not linked: 5
- Chlebowski, 1989, Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group, Br J Cancer, 59, 227, 10.1038/bjc.1989.46 · doi:10.1038/bjc.1989.46
- Titgan, 1997, Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone, Proc Am Soc Clin Oncol, 16, 288a
- Honecker, 2002, Reduction of skin toxicity of pegylated lipsomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: a phase I/II trial, J Cancer Res Clin Oncol, 128, 848
- Baas, 2000, Caelyx in malignant mesothelioma: a phase II EORTC study, Ann Oncol, 11, 697, 10.1023/A:1008346925273 · doi:10.1023/a:1008346925273
- Clin Oncol, 2000, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 18, 3115, 10.1200/JCO.2000.18.17.3115 · doi:10.1200/jco.2000.18.17.3115
Cited by
Items 101–118 of 118
Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles
Cai, S., Yang, Q., Bagby, T. R., & Forrest, M. L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.017 · Cited by 252
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Future of the Particle Replication in Nonwetting Templates (PRINT) Technology
Xu, J., Wong, D. H. C., Byrne, J. D., Chen, K., Bowerman, C., & DeSimone, J. M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209145 · Cited by 208
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Füredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Imaging-assisted anticancer nanotherapy
Dasgupta, A., Biancacci, I., Kiessling, F., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.38288 · Cited by 74
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Zhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49
Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines
Upshaw, J. N., Parson, S. K., Buchsbaum, R. J., Schlam, I., Ruddy, K. J., Durani, U., Epperla, N., & Leong, D. P. (2024) · JACC: CardioOncology · doi:10.1016/j.jaccao.2024.02.004 · Cited by 49
Allison, S. D. (2007) · Journal of Infusion Nursing · doi:10.1097/01.nan.0000264712.26219.67 · Cited by 45
Zhang, B., Jiang, T., Tuo, Y., Jin, K., Luo, Z., Shi, W., Mei, H., Hu, Y., Pang, Z., & Jiang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.007 · Cited by 41
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
Lyseng-Williamson, K. A., Duggan, S. T., & Keating, G. M. (2013) · BioDrugs · doi:10.1007/s40259-013-0070-1 · Cited by 36
Pegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series
Glas, M., Koch, H., Hirschmann, B., Jauch, T., Steinbrecher, A., Herrlinger, U., Bogdahn, U., & Hau, P. (2007) · Oncology · doi:10.1159/000113052 · Cited by 30
Dou, Y. N., Chaudary, N., Chang, M. C., Dunne, M., Huang, H., Jaffray, D. A., Milosevic, M., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.039 · Cited by 21
Metadata
- Authors
- O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 15
- Issue
- 3
- Pages
- 440-449
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2096593771
- Cited by
- 1,738
- References
- 23
- FWCI
- 28.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5790 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.